학술논문
334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection
Document Type
Abstract
Author
Source
In Annals of Oncology September 2020 31 Supplement 4:S380-S380
Subject
Language
ISSN
0923-7534